SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States.
$2.74-5.19%
报价 2026-11-13
市值
$196.9M
EV
–
PE (TTM)
–
预期 PE (FY2026)
1.6x
52 周区间距高点 -60.6%
$2.74$6.95
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SIGASIGA Technologies, Inc. | $196.9M | -5.2% | -32.0% | – | – | – | – | |
| RIGLRigel Pharmaceuticals, Inc. | $837.2M | -2.7% | +4.5% | 91.4% | 2.7x | 9.1x | 11.1x | |
| OLMAOlema Pharmaceuticals, Inc. | $662.3M | +0.5% | – | 0% | – | – | – | |
| AQSTAquestive Therapeutics, Inc. | $491.4M | +9.5% | +10.5% | 58.4% | – | – | – | |
| CTMXCytomX Therapeutics, Inc. | $444.7M | -4.2% | -73.6% | 99.3% | – | – | – | |
| SNDLSNDL Inc. | $335.3M | -1.4% | – | 19% | – | 8.8x | – | |
| EBSEmergent BioSolutions Inc. | $297.7M | -1.7% | -20.1% | 49.4% | – | – | 4.3x | |
| ORGOOrganogenesis Holdings Inc. | $105.2M | -16.1% | -44.9% | 62% | – | – | – | |
| DRIODarioHealth Corp. | $12.3M | -23.6% | +17.4% | 56.1% | 3.5x | – | – | |
| 同行中位数 | – | – | -7.8% | 57.2% | 3.1x | 9.0x | 7.7x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。